Search Results for: us stem cell

Weekly reads: oocytes from males, David Sinclair longevity inc, diabetes, He Jiankui

/ / Leave a Comment
David Sinclair

A team led by Harvard professor David Sinclair had a recent Cell paper on reprogramming to fight aging that I reviewed here on The Niche. I thought the paper was exciting and important. Note that in vivo reprogramming was first done more than a decade ago. Sinclair did have a novel fast-forward aging method and overall […]

Weekly reads: oocytes from males, David Sinclair longevity inc, diabetes, He Jiankui Read More »

Review of where Kimera Labs fits into sphere of exosome companies

/ / 4 Comments
Kimera labs exosome

Today’s post takes a close look at the exosome manufacturer Kimera Labs in the context of the main exosome companies. What are exosomes? Exosomes are microscopic bubbles or vesicles produced by cells. Exosomes contain many cellular substances that are biologically active. Some of these materials may be helpful clinically, while others could pose risks. Clinical outcomes

Review of where Kimera Labs fits into sphere of exosome companies Read More »

Weekly reads: big CRISPR mtg, Mesoblast good news, Neuralink spiked

/ / 1 Comment
Victoria Gray, CRISPR meeting

Where do things stand with potential applications of CRISPR and other gene editing technologies in patients? Overall, things are looking very positive. CRISPR human trials This week the third big international human genome editing meeting took place in London. The summit addressed numerous potential clinical applications. It was good to see the agenda included quite

Weekly reads: big CRISPR mtg, Mesoblast good news, Neuralink spiked Read More »

Weekly reads: human CRISPR, MRT risks, private IRBs, skincare

/ / Leave a Comment
David Liu, human CRISPR

It’s funny how sometimes there are many new articles about one general topic like this week with heritable (and somatic) human CRISPR gene editing and related tech.  There are clear reasons for optimism in the somatic arena given advancing trials. Germline editing remains highly questionable in my view even just technically. Then there are loads

Weekly reads: human CRISPR, MRT risks, private IRBs, skincare Read More »

Weekly reads: He Jiankui disappoints, ALS, Vor Biopharma

/ / Leave a Comment
He Jiankui

I’m sure many of you remember He Jiankui, the guy who made CRISPR babies. He ended up serving three years in jail in China. He seems to be trying for something of a comeback since his release. Were He Jiankui invitations a mistake? Some prestigious places have even invited him to give talks, which seemed

Weekly reads: He Jiankui disappoints, ALS, Vor Biopharma Read More »

Weekly reads: De-extinction pros & cons with Dodo 2.0, CTCF, retraction

/ / 3 Comments
Dodo bird de-extinction, de-extinction

I don’t think de-extinction of animals just for the heck of it like woolly mammoths is a good idea, but what about de-extincting animals like the Dodo? Where humans caused them to disappear? If that’s even possible, is it a good idea? Dodo de-extinction A company is giving it a try. I can see the

Weekly reads: De-extinction pros & cons with Dodo 2.0, CTCF, retraction Read More »

Skepticism on the Bryan Johnson anti-aging extravaganza

/ / 1 Comment
Oliver Zolman, Bryan Johnson

Near-billionaire Bryan Johnson apparently does not like getting old and he’s trying to do something transformative about it. He and his team are experimenting in a big way.  As a 55-year-old myself, I can’t blame him for wanting to fight aging in general. However, his anti-aging project includes some extreme stuff. Will some in the

Skepticism on the Bryan Johnson anti-aging extravaganza Read More »